Bristol Myers Squibb Company $BMY Holdings Cut by Graves Light Lenhart Wealth Inc.

Graves Light Lenhart Wealth Inc. decreased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 11.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,863 shares of the biopharmaceutical company’s stock after selling 658 shares during the quarter. Graves Light Lenhart Wealth Inc.’s holdings in Bristol Myers Squibb were worth $225,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Mirador Capital Partners LP raised its holdings in shares of Bristol Myers Squibb by 1.0% during the 2nd quarter. Mirador Capital Partners LP now owns 48,662 shares of the biopharmaceutical company’s stock valued at $2,253,000 after purchasing an additional 496 shares in the last quarter. Seneca House Advisors lifted its stake in shares of Bristol Myers Squibb by 15.7% in the 2nd quarter. Seneca House Advisors now owns 5,010 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 681 shares during the last quarter. Krilogy Financial LLC lifted its stake in shares of Bristol Myers Squibb by 6.0% in the 2nd quarter. Krilogy Financial LLC now owns 11,592 shares of the biopharmaceutical company’s stock valued at $537,000 after purchasing an additional 651 shares during the last quarter. Fiduciary Alliance LLC lifted its stake in shares of Bristol Myers Squibb by 209.8% in the 2nd quarter. Fiduciary Alliance LLC now owns 13,159 shares of the biopharmaceutical company’s stock valued at $609,000 after purchasing an additional 8,912 shares during the last quarter. Finally, Byrne Asset Management LLC lifted its stake in shares of Bristol Myers Squibb by 72.0% in the 2nd quarter. Byrne Asset Management LLC now owns 2,148 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 899 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 0.1%

Shares of NYSE BMY opened at $46.30 on Wednesday. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The company has a market cap of $94.24 billion, a PE ratio of 18.67, a P/E/G ratio of 2.37 and a beta of 0.35. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a 50-day moving average of $47.06 and a two-hundred day moving average of $49.95.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the previous year, the firm posted $2.07 earnings per share. The company’s revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BMY has been the subject of several analyst reports. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. Citigroup dropped their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Finally, Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $56.38.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.07% of the stock is currently owned by company insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.